Article
Phase II open-label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid-Lung-A.
Thoracic cancer - 1 Feb 2021
Park Cheol-Kyu, Lee Sung-Yong, Lee Jae Cheol, Choi Chang-Min, Lee Shin Yup, Jang Tae-Won, Oh In-Jae, Kim Young-Chul
Abstract excerpt
BACKGROUND: Mutation analysis of circulating tumor DNA (ctDNA) is used for diagnosing lung cancer. This trial aimed to assess the efficacy of afatinib in treatment-naïve patients with lung cancer harboring epidermal growth factor receptor mutations (EGFRm, exon 19 deletions or exon 21 point mutations) detected based on ctDNA. METHODS: The primary objective was the objective response rate (ORR) in the response...
Topics
- Afatinib
- Aged
- Antineoplastic Agents
- Circulating Tumor DNA
- ErbB Receptors
- Female
- Humans
- Lung Neoplasms
- Male
- Mutation
- Prospective Studies